MAPT and Cognitive impairment: While first-generation tau tracers suffered from off-target binding [5, 6] and a resulting large inter- and intra-case variability [7], second-generation tau-PET tracers showed promising first results in vivo with specific binding in affected regions in patients with mild cognitive impairment and AD compared to healthy controls [8–11].